Financial Ratios Siemens Healthineers AG
Equities
SHL
DE000SHL1006
Advanced Medical Equipment & Technology
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 43.30 EUR | -1.84% |
|
-6.48% | -3.61% |
| 01-23 | SIEMENS HEALTHINEERS : Receives a Buy rating from Berenberg | ZD |
| 01-22 | SIEMENS HEALTHINEERS : UBS reiterates its Neutral rating | ZD |
| Fiscal Period: September | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
Profitability | ||||||||||
Return on Assets | 4.75 | 4.02 | 2.78 | 3.79 | 4.37 | |||||
Return on Total Capital | 6.57 | 5.47 | 3.74 | 5.07 | 5.87 | |||||
Return On Equity % | 12.1 | 11.45 | 8.03 | 10.77 | 11.93 | |||||
Return on Common Equity | 11.99 | 11.36 | 7.96 | 10.71 | 11.83 | |||||
Margin Analysis | ||||||||||
Gross Profit Margin % | 38.63 | 37.47 | 35.56 | 37.87 | 38.63 | |||||
SG&A Margin | 15.65 | 15.69 | 16.64 | 16.46 | 16.63 | |||||
EBITDA Margin % | 18.31 | 18.15 | 14.81 | 16.71 | 17.43 | |||||
EBITA Margin % | 15.79 | 15.63 | 12.16 | 14.37 | 15.22 | |||||
EBIT Margin % | 14.21 | 13.47 | 9.84 | 12.56 | 13.54 | |||||
Income From Continuing Operations Margin % | 9.7 | 9.46 | 7.03 | 8.76 | 9.27 | |||||
Net Income Margin % | 9.6 | 9.39 | 6.96 | 8.68 | 9.17 | |||||
Net Avail. For Common Margin % | 9.6 | 9.39 | 6.96 | 8.68 | 9.17 | |||||
Normalized Net Income Margin | 8.52 | 7.98 | 5.48 | 6.98 | 7.53 | |||||
Levered Free Cash Flow Margin | 27.48 | 5.01 | 4.8 | 9.08 | 10.64 | |||||
Unlevered Free Cash Flow Margin | 27.77 | 5.35 | 5.66 | 10.41 | 11.78 | |||||
Asset Turnover | ||||||||||
Asset Turnover | 0.54 | 0.48 | 0.45 | 0.48 | 0.52 | |||||
Fixed Assets Turnover | 6.2 | 6.27 | 5.91 | 5.91 | 6.01 | |||||
Receivables Turnover (Average Receivables) | 2.91 | 3.59 | 3.27 | 3.56 | 3.61 | |||||
Inventory Turnover (Average Inventory) | 4.03 | 3.78 | 3.37 | 3.28 | 3.45 | |||||
Short Term Liquidity | ||||||||||
Current Ratio | 1.08 | 1.11 | 1.05 | 1.25 | 1.11 | |||||
Quick Ratio | 0.73 | 0.71 | 0.68 | 0.85 | 0.75 | |||||
Operating Cash Flow to Current Liabilities | 0.29 | 0.21 | 0.16 | 0.24 | 0.28 | |||||
Days Sales Outstanding (Average Receivables) | 125.62 | 101.57 | 111.78 | 102.81 | 101.23 | |||||
Days Outstanding Inventory (Average Inventory) | 90.6 | 96.62 | 108.46 | 111.59 | 105.77 | |||||
Average Days Payable Outstanding | 50.36 | 53.85 | 58.04 | 57.9 | 56.84 | |||||
Cash Conversion Cycle (Average Days) | 165.86 | 144.34 | 162.2 | 156.49 | 150.17 | |||||
Long Term Solvency | ||||||||||
Total Debt/Equity | 87.62 | 83.89 | 91.84 | 88.83 | 81.78 | |||||
Total Debt / Total Capital | 46.7 | 45.62 | 47.87 | 47.04 | 44.99 | |||||
LT Debt/Equity | 74.45 | 69.57 | 67.6 | 73.73 | 62.69 | |||||
Long-Term Debt / Total Capital | 39.68 | 37.83 | 35.24 | 39.05 | 34.49 | |||||
Total Liabilities / Total Assets | 61.25 | 59.53 | 61.16 | 60.38 | 59.23 | |||||
EBIT / Interest Expense | 30.81 | 24.78 | 7.21 | 5.9 | 7.44 | |||||
EBITDA / Interest Expense | 41.81 | 35.12 | 11.58 | 8.29 | 10.08 | |||||
(EBITDA - Capex) / Interest Expense | 33.69 | 27.9 | 8.75 | 6.82 | 8.16 | |||||
Total Debt / EBITDA | 4.13 | 4.02 | 4.86 | 4.11 | 3.45 | |||||
Net Debt / EBITDA | 3.74 | 3.67 | 4.38 | 3.43 | 2.94 | |||||
Total Debt / (EBITDA - Capex) | 5.12 | 5.06 | 6.43 | 4.99 | 4.27 | |||||
Net Debt / (EBITDA - Capex) | 4.65 | 4.62 | 5.8 | 4.16 | 3.64 | |||||
Growth Over Prior Year | ||||||||||
Total Revenues, 1 Yr. Growth % | 24.46 | 20.65 | -0.16 | 3.15 | 4.53 | |||||
Gross Profit, 1 Yr. Growth % | 24.59 | 17.05 | -5.26 | 9.85 | 6.64 | |||||
EBITDA, 1 Yr. Growth % | 31.73 | 19.17 | -18.52 | 15.7 | 9.05 | |||||
EBITA, 1 Yr. Growth % | 33.11 | 18.93 | -22.31 | 21.89 | 10.74 | |||||
EBIT, 1 Yr. Growth % | 31.53 | 13.86 | -27.05 | 31.69 | 12.64 | |||||
Earnings From Cont. Operations, 1 Yr. Growth % | 22.63 | 17.76 | -25.79 | 28.46 | 10.62 | |||||
Net Income, 1 Yr. Growth % | 22.4 | 18.01 | -25.96 | 28.69 | 10.4 | |||||
Normalized Net Income, 1 Yr. Growth % | 28.94 | 16.83 | -31.42 | 31.19 | 12.84 | |||||
Diluted EPS Before Extra, 1 Yr. Growth % | 12.14 | 15.29 | -25.97 | 29.1 | 10.4 | |||||
Accounts Receivable, 1 Yr. Growth % | -17.23 | 17.08 | 3.73 | 4.08 | 2.37 | |||||
Inventory, 1 Yr. Growth % | 37.98 | 26.11 | 7.11 | -2.68 | -1.05 | |||||
Net Property, Plant and Equip., 1 Yr. Growth % | 31.27 | 10.23 | 2.01 | 4.4 | 1.22 | |||||
Total Assets, 1 Yr. Growth % | 68.02 | 17 | -4.84 | -1.35 | -3.66 | |||||
Tangible Book Value, 1 Yr. Growth % | -707.36 | -16.39 | -2.19 | -15.95 | -14.34 | |||||
Common Equity, 1 Yr. Growth % | 30.59 | 23.69 | -8.85 | 0.65 | -0.87 | |||||
Cash From Operations, 1 Yr. Growth % | 52.13 | -14.63 | -15.38 | 33.36 | 24.98 | |||||
Capital Expenditures, 1 Yr. Growth % | 21.01 | 26.41 | -1.64 | -16.95 | 17.53 | |||||
Levered Free Cash Flow, 1 Yr. Growth % | -473.93 | -78.43 | -4.29 | 22.05 | 22.49 | |||||
Unlevered Free Cash Flow, 1 Yr. Growth % | -491.93 | -77.2 | 5.56 | 25.93 | 18.25 | |||||
Dividend Per Share, 1 Yr. Growth % | 6.25 | 11.76 | 0 | 0 | 5.26 | |||||
Compound Annual Growth Rate Over Two Years | ||||||||||
Total Revenues, 2 Yr. CAGR % | 11.34 | 22.54 | 9.76 | 1.48 | 3.84 | |||||
Gross Profit, 2 Yr. CAGR % | 9.52 | 20.76 | 5.3 | 2.01 | 8.23 | |||||
EBITDA, 2 Yr. CAGR % | 8.4 | 25.5 | -1.46 | -2.64 | 12.32 | |||||
EBITA, 2 Yr. CAGR % | 7.75 | 26.06 | -3.88 | -2.69 | 16.18 | |||||
EBIT, 2 Yr. CAGR % | 5.53 | 22.64 | -8.86 | -1.99 | 21.79 | |||||
Earnings From Cont. Operations, 2 Yr. CAGR % | 4.93 | 20.17 | -6.52 | -2.36 | 19.2 | |||||
Net Income, 2 Yr. CAGR % | 4.98 | 20.18 | -6.52 | -2.38 | 19.2 | |||||
Normalized Net Income, 2 Yr. CAGR % | 6.47 | 20.77 | -10.49 | -5.14 | 21.67 | |||||
Diluted EPS Before Extra, 2 Yr. CAGR % | 0.06 | 13.7 | -7.61 | -2.23 | 19.39 | |||||
Accounts Receivable, 2 Yr. CAGR % | 14.17 | -1.94 | 10.2 | -0.86 | 3.22 | |||||
Inventory, 2 Yr. CAGR % | 24.11 | 31.91 | 16.22 | 2.1 | -1.87 | |||||
Net Property, Plant and Equip., 2 Yr. CAGR % | 30.19 | 20.29 | 6.04 | 3.2 | 2.79 | |||||
Total Assets, 2 Yr. CAGR % | 40.27 | 39.82 | 5.52 | -3.11 | -2.51 | |||||
Tangible Book Value, 2 Yr. CAGR % | 386.65 | 126.43 | -9.57 | -9.33 | -15.15 | |||||
Common Equity, 2 Yr. CAGR % | 29.26 | 25.98 | 6.18 | -4.22 | -0.11 | |||||
Cash From Operations, 2 Yr. CAGR % | 34.68 | 13.96 | -15 | 6.24 | 29.11 | |||||
Capital Expenditures, 2 Yr. CAGR % | 7.89 | 23.68 | 11.5 | -9.62 | -1.2 | |||||
Levered Free Cash Flow, 2 Yr. CAGR % | 65.42 | -9.31 | -54.56 | 36.65 | 22.27 | |||||
Unlevered Free Cash Flow, 2 Yr. CAGR % | 62.86 | -4.55 | -50.94 | 41.59 | 22.03 | |||||
Dividend Per Share, 2 Yr. CAGR % | 3.08 | 8.97 | 5.72 | 0 | 2.6 | |||||
Compound Annual Growth Rate Over Three Years | ||||||||||
Total Revenues, 3 Yr. CAGR % | 10.25 | 14.36 | 14.45 | 7.51 | 2.49 | |||||
Gross Profit, 3 Yr. CAGR % | 8.33 | 11.97 | 11.38 | 6.8 | 3.53 | |||||
EBITDA, 3 Yr. CAGR % | 11.03 | 12 | 8.67 | 4.15 | 1.11 | |||||
EBITA, 3 Yr. CAGR % | 10.42 | 11.5 | 7.28 | 4.04 | 1.6 | |||||
EBIT, 3 Yr. CAGR % | 9.25 | 8.39 | 3.14 | 3.04 | 2.66 | |||||
Earnings From Cont. Operations, 3 Yr. CAGR % | 10.77 | 9.04 | 2.33 | 3.93 | 1.78 | |||||
Net Income, 3 Yr. CAGR % | 10.93 | 9.16 | 2.26 | 3.99 | 1.7 | |||||
Normalized Net Income, 3 Yr. CAGR % | 11.51 | 8.64 | 0.01 | 1.68 | 0.51 | |||||
Diluted EPS Before Extra, 3 Yr. CAGR % | 7.61 | 4.9 | -1.45 | 3.29 | 1.81 | |||||
Accounts Receivable, 3 Yr. CAGR % | 8.31 | 14.84 | -0.08 | 4.8 | 0.21 | |||||
Inventory, 3 Yr. CAGR % | 20.23 | 24.77 | 23.06 | 9.55 | 1.04 | |||||
Net Property, Plant and Equip., 3 Yr. CAGR % | 26.39 | 23.16 | 13.86 | 5.49 | 2.53 | |||||
Total Assets, 3 Yr. CAGR % | 28.74 | 31.79 | 22.99 | 3.18 | -3.29 | |||||
Tangible Book Value, 3 Yr. CAGR % | 105.02 | 171.41 | 71.17 | -11.75 | -11.03 | |||||
Common Equity, 3 Yr. CAGR % | 23.54 | 26.63 | 13.1 | 4.31 | -3.11 | |||||
Cash From Operations, 3 Yr. CAGR % | 22.51 | 15.69 | 3.2 | -1.23 | 12.15 | |||||
Capital Expenditures, 3 Yr. CAGR % | 8.34 | 13.74 | 14.59 | 1.08 | -1.35 | |||||
Levered Free Cash Flow, 3 Yr. CAGR % | 26.46 | -15.57 | -7.66 | -26.15 | 31.75 | |||||
Unlevered Free Cash Flow, 3 Yr. CAGR % | 24.76 | -14.89 | -1.29 | -22.97 | 33.34 | |||||
Dividend Per Share, 3 Yr. CAGR % | 6.69 | 5.9 | 5.9 | 3.78 | 1.72 | |||||
Compound Annual Growth Rate Over Five Years | ||||||||||
Total Revenues, 5 Yr. CAGR % | 5.85 | 9.69 | 10.05 | 9.02 | 10.08 | |||||
Gross Profit, 5 Yr. CAGR % | 4.92 | 7.4 | 7.11 | 7.88 | 10.11 | |||||
EBITDA, 5 Yr. CAGR % | 4.44 | 7.59 | 5.92 | 5.9 | 10.24 | |||||
EBITA, 5 Yr. CAGR % | 4.14 | 7.24 | 4.54 | 5.59 | 10.75 | |||||
EBIT, 5 Yr. CAGR % | 3.85 | 5.63 | 1.7 | 4.12 | 10.23 | |||||
Earnings From Cont. Operations, 5 Yr. CAGR % | 5.61 | 8.04 | 3.5 | 4.33 | 8.78 | |||||
Net Income, 5 Yr. CAGR % | 5.67 | 8.13 | 3.59 | 4.38 | 8.73 | |||||
Normalized Net Income, 5 Yr. CAGR % | 5.34 | 7.3 | 1.47 | 2.9 | 8.17 | |||||
Diluted EPS Before Extra, 5 Yr. CAGR % | 3.67 | 5.59 | 1.24 | 1.98 | 6.41 | |||||
Accounts Receivable, 5 Yr. CAGR % | -1.44 | 3.11 | 8.9 | 8.28 | -0.65 | |||||
Inventory, 5 Yr. CAGR % | 19.44 | 20.09 | 18.61 | 15.15 | 12.41 | |||||
Net Property, Plant and Equip., 5 Yr. CAGR % | 18.19 | 20.61 | 17.82 | 14.75 | 9.3 | |||||
Total Assets, 5 Yr. CAGR % | 15.75 | 18.37 | 18.76 | 16.53 | 12.07 | |||||
Tangible Book Value, 5 Yr. CAGR % | 4.59 | 4.94 | 48.06 | 75.05 | 29.27 | |||||
Common Equity, 5 Yr. CAGR % | 47.05 | 43.31 | 15.87 | 13.25 | 7.62 | |||||
Cash From Operations, 5 Yr. CAGR % | 9.67 | 4.86 | 5.85 | 11.81 | 12.87 | |||||
Capital Expenditures, 5 Yr. CAGR % | 9.71 | 12.83 | 9.6 | 3.75 | 7.99 | |||||
Levered Free Cash Flow, 5 Yr. CAGR % | 32.26 | 12.54 | -15.7 | 2.36 | 13.47 | |||||
Unlevered Free Cash Flow, 5 Yr. CAGR % | 29.78 | 8.59 | -13.78 | 4.33 | 16.65 | |||||
Dividend Per Share, 5 Yr. CAGR % | - | - | 6.3 | 3.5 | 4.56 |
- Stock Market
- Equities
- SHL Stock
- Financials Siemens Healthineers AG
- Financial Ratios
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition















